Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Newsoara Bio Enters $171 Million Agreement for Oncolytic Viruses

publication date: Sep 29, 2021

Shanghai Newsoara BioPharma in-licensed greater China rights to a Phase III oncolytic virus and other oncolytic viruses from Genelux in a $171 million deal. Newsoara will pay $10 million initially and up to $161 million in milestone payments, plus royalties. It will have manufacturing rights and be responsible for China development of Olvi-Vec. Genelux is currently planning a US Phase III trial of the candidate as a second-line therapy for ovarian cancer. Newsoara will also have exclusive China rights to other products from Genelux's oncolytic virus platform. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here